Clinical trials: Knee OA
Osteoarthritis, Knee
Osteoarthritis Knee Pain Relief Study of 0.25% 920-CGS-200
This is a study of an over-the-counter, capsaicin-based (0.25%) topical analgesic for management of osteoarthritis knee pain meeting the US Food and Drug Administration's (FDAs) Tentative Final Monograph (TFM) guidance for…
- Trial name
- NCT03124407
- Testing
- Capsaicin Topical Solution, Drug product vehicle
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Propella Therapeutics
Knee Osteoarthritis (OA)
A Clinical Study to Evaluate the Efficacy of Native CT-II® in Individuals With Knee Osteoarthritis
This randomized, double-blind, placebo-controlled clinical study evaluates the efficacy of Native CT-II® (undenatured type II collagen) in individuals with knee osteoarthritis using a parallel design.Participants are assigned to…
- Trial name
- NCT06917287
- Testing
- Native CT-II® (undenatured type II collagen), Glucosamine HCL + Chondroitin Sulphate (G+C) [Comparator]
- Where
- 5 sites in India
- Volunteers
- 114 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Knee Osteoarthritis, Knee Osteoarthritis (Knee OA)
Efficacy of Platelet-Rich Plasma Added to Hyaluronic Acid in Knee Osteoarthritis
This prospective, randomized, open-label, single-centre post-market clinical follow-up (PMCF) study evaluates the clinical performance and safety of a single intra-articular injection of hyaluronic acid (HA) combined with…
- Conditions
- Knee Osteoarthritis, Knee Osteoarthritis (Knee OA), Knee Osteoarthritis (OA), Osteoarthritis (OA) of the Knee
- Trial name
- NCT07785401
- Testing
- Hyaluronic Acid (HA) and Platelet rich plasma (PRP), Hyaluronic Acid (HA)
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Implai Sp z o.o
Obesity, Knee Osteoarthritis (OA)
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis.
- Trial name
- AMAZE 5 (NCT07481630)
- Testing
- NNC0487-0111
- Where
- 82 sites in United States, Australia and 8 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Osteoarthritis (OA) of the Medial Knee Compartment
European Post-Market Study for Medial Knee Osteoarthritis Treated With the Atlas Knee System for Load Reduction
The objective of this study is to collect post market data on safety and performance of the Atlas Knee System in patients with osteoarthritis (OA) of the medial knee compartment through a 24 months post-operative follow-up period.
- Trial name
- Atlas-PMCF (NCT02663414)
- Testing
- Atlas Knee System
- Sponsor
- Moximed
Joint Disease
Autologous Plasma Rich in Growth Factors (PRGF) Treating the Symptomatic Knee OA
The purpose of this study is to evaluate the efficacy and safety of PRGF infiltrations in the treatment of knee osteoarthritis.
- Trial name
- NCT00782197
- Testing
- PRGF Intraarticular injection, Hyaluronic Acid Intraarticular injection
- Where
- 3 sites in Spain
- Volunteers
- 240 people
- Sponsor
- Biotechnology Institute IMASD
Osteoarthritis, Knee
HKT-500-US12 In Adult Patients With OA Knee Pain
The objective of this study is to characterize the analgesic properties of single dose study of HKT-500 in subjects with pain caused by mild to moderate OA of the knee
- Trial name
- NCT00647231
- Testing
- HKT-500 Topical Patch
- Where
- 29 sites in United States
- Volunteers
- 300 people
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
Pain, Inflammatory
A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)
This study is the first administration of GSK3858279 in humans and will be conducted in two parts: Part A will consist of a single ascending dose escalation design to evaluate safety, tolerability, PK, TE and immunogenicity of…
- Trial name
- NCT03485365
- Testing
- GSK3858279 IV, GSK3858279 SC
- Where
- 5 sites in Germany, Poland and 1 more
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoarthritis, Knee
Assess the Blood-Oxygen-Level-Dependent (BOLD) Signal Changes in the Brain by Paracetamol as Measured by Functional Magnetic Resonance Imaging (fMRI) in Subjects With Osteoarthritis (OA)
Blood-Oxygen-Level-Dependent (BOLD) responses to painful mechanical stimulation of the OA knee following treatment with four consecutive doses (at 8 hour intervals) on giving sustained released paracetamol treatment or placebo…
- Trial name
- NCT01105936
- Testing
- Paracetamol
- Where
- Spain
- Volunteers
- 31 people
- Sponsor
- GlaxoSmithKline
Osteoarthritis of the Knee
Efficacy and Safety of 3 Different Dosage Regimens of Hyaluronic Acid in Patients With Knee Osteoarthritis (OA)
The main objective is the comparison of three different dosage regimens of hyaluronic acid in the treatment of osteoarthritis of the knee.
- Trial name
- NCT01290497
- Testing
- Hyaluronic acid 5 x 2.5 ml, Hyaluronic acid 1 x 5 ml, Hyaluronic acid 2 x 5 ml
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Tedec-Meiji Farma, S.A.
Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain
The purpose of this study is to evaluate the safety and efficacy of GRT6005 compared to placebo in patients with moderate to severe chronic pain due to osteoarthritis (OA) of the knee.
- Trial name
- NCT01709214
- Testing
- Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Oxycodone CR
- Where
- 83 sites in United States
- Volunteers
- 619 people
- Sponsor
- Tris Pharma, Inc.
Osteoarthritis, Pain
Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of fulranumab as adjunctive therapy compared with placebo in participants with chronic moderate to severe pain and functional impairment from knee…
- Trial name
- NCT02336685
- Testing
- Fulranumab 1 mg, Fulranumab 3 mg, Opioid
- Where
- 53 sites in United States, Canada and 4 more
- Volunteers
- 79 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Pain
A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, 200, 300 and 400 mg) of Extended-release Tramadol HCl With Placebo for the Treatment of Osteoarthritis(OA) of the Knee and/or Hip
The purpose of this study is to compare the effectiveness of multiple doses of once daily tramadol HCl ER (100, 200, 300 and 400 mg) to placebo in patients with moderate to severe pain due to OA.
- Trial name
- NCT00325858
- Testing
- Tramadol HCl ER
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Bausch Health Americas, Inc.
Knee Osteoarthritis, Knee Osteoarthritis (Knee OA)
Efficacy of Platelet-Rich Plasma Combined With Hyaluronic Acid in Knee Osteoarthritis
This prospective, randomized, open-label, single-centre post-market clinical follow-up (PMCF) study evaluates the clinical performance and safety of a single intra-articular injection of hyaluronic acid (HA) combined with…
- Conditions
- Knee Osteoarthritis, Knee Osteoarthritis (Knee OA), Knee Osteoarthritis (OA), Osteoarthritis (OA) of the Knee
- Trial name
- NCT07784907
- Testing
- Hyaluronic Acid (HA) and Platelet rich plasma (PRP), Hyaluronic Acid (HA)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Implai Sp z o.o
Osteoarthritis of the Knee
Efficacy and Safety of Repeated Intraarticular Injections of Hyaluronic Acid in Patients With OA of the Knee
The main objective is the long-term comparison (3 years and 4 months) of the efficacy and safety of repeated intra-articular administration of hyaluronic acid in the treatment of osteoarthritis of the knee.
- Trial name
- NCT00669032
- Testing
- Hyaluronic acid
- Volunteers
- 446 people
- Sponsor
- Tedec-Meiji Farma, S.A.
Osteoarthritis, Knee
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA
This study is a multi-center, randomized, placebo-controlled, double-blind clinical study, consisting of Part 1 (Phase 1b) in a sequential, dose-escalating design and Part 2 (Phase 2) in a parallel design.
- Trial name
- NCT05237752
- Testing
- LG00034053
- Where
- 2 sites in Australia, South Korea
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- LG Chem
Osteoarthritis (OA) of the Knee
2ccPA Study in Patients With Symptomatic Knee Osteoarthritis
This clinical trial is designed to determine safety and tolerability as well as the MTD of a single-dose 2ccPA and PK data in symptomatic knee OA.
- Trial name
- NCT04229394
- Testing
- 2ccPA
- Where
- 5 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- Orient Europharma Co., Ltd.
Osteoarthritis of the Knee
Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients
This trial is a Phase IIa, Randomized, Double blinded, Placebo controlled, Dose finding Study to investigate the safety and efficacy of TLC599 in subjects with osteoarthritis of the knee.
- Trial name
- NCT03005873
- Testing
- TLC599 LD group, Normal Saline, TLC599 HD group
- Where
- 13 sites in Australia, Taiwan
- Volunteers
- 76 people
- Sponsor
- Taiwan Liposome Company
Osteoarthritis of the Knee
Efficacy and Safety Study of Glucosamine/Chondroitin Sulfate to Patients Treatment With Osteoarthrosis of the Knee
The purpose of this study is to assess the efficacy and safety of glucosamine and chondroitin sulfate association in the treatment of patients with osteoarthrosis of the knee.
- Trial name
- Artico (NCT00955552)
- Testing
- Glucosamine sulphate and chondroitin sulphate association, Cosamin DS® (Nutramax)
- Where
- 4 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Eurofarma Laboratorios S.A.
Moderate to Severe Osteoarthritis
Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)
The purpose of this study is to find the optimal dose of SM04690 that can be safely given by intra-articular injection into the target knee joint of subjects with moderate to severe osteoarthritis.
- Trial name
- NCT02095548
- Testing
- SM04690, 0.03mg/2mL, SM04690, 0.07mg/2mL, SM04690, 0.23mg/2mL
- Where
- 7 sites in United States
- Volunteers
- 61 people
- Sponsor
- Biosplice Therapeutics, Inc.